Revenue growth is strong but margin compression from rising medical costs is the key watch item. The raised EBITDA guidance suggests management sees some stabilization; monitor next quarter's medical expense ratio and any further guidance changes.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $4.54entry
- T+1 · 11d ago +0.88%α +0.57% · $4.58
- T+5 · 5d ago +5.07%α +1.78% · $4.77
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Evolent Health reported Q3 2026 revenue of $725.4M, up 51% YoY, and adjusted EPS of $0.06, in line with consensus of $0.06. The company reiterated full-year revenue guidance of $2.6B-$2.7B and raised its Adjusted EBITDA guidance to $130M-$135M. Revenue growth was driven by strong Performance Suite expansion, but the medical expense ratio deteriorated to 93.0% from 85.0% a year ago, pressuring margins.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $725.4M vs $479.5M YoY (+51%)
- Adjusted EPS $0.06, in line with $0.06 consensus
- GAAP net loss $23.6M vs $26.9M YoY, loss per share $0.21 vs $0.24
- Adjusted EBITDA $34.3M vs $39.0M YoY, margin 4.7% vs 8.1%
- Full-year 2026 revenue guidance reiterated at $2.6B-$2.7B
- Full-year 2026 Adjusted EBITDA guidance raised to $130M-$135M
- Medical expense ratio 93.0% vs 85.0% YoY, reflecting higher claims costs
- Renewed largest Surgical Management customer for 4 years; expanded oncology services with two clients
Financial Impact
Revenue grew 51% YoY to $725.4M; adjusted EBITDA margin compressed from 8.1% to 4.7% due to rising medical costs
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Performance Suite | $564.3M | +96.7% |
| Specialty Technology and Services Suite | $72.8M | -21.9% |
| Administrative Services | $48.3M | -16.5% |
| Cases | $40.0M | -3.8% |
Risk Factors
- Medical expense ratio rose to 93.0% from 85.0% YoY, indicating cost pressure
- Adjusted EBITDA margin declined to 4.7% from 8.1% YoY
- GAAP net loss continues, though narrowed YoY
- High dependence on a few large partners for revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302930014 |
Track record
8 reports on EVH
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $4.82 Now $4.83 −0.31% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $4.74 Now $4.83 −1.90% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $4.54 Now $4.83 +6.39% settles Dec 4
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $3.59 to $4.26 Now $4.83 +34.54% ▲ +18.66% +18.06% vs SPY
- Jul 8, 202618w ago Press Release Neutral 1/10 Entry $5.63 to $3.59 Now $4.83 −14.21% ▼ −36.23% −38.48% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $3.47 to $3.83 Now $4.83 +39.19% ▲ +10.37% +5.42% vs SPY
- Feb 24, 202637w ago 8-K Mixed 6/10 Entry $3.14 to $2.27 Now $4.83 +53.82% ▼ −27.71% −22.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers